1110018J18Rik Activators
The 1110018J18Rik activators encompass a diverse range of chemical compounds that enhance the protein's activity by influencing specific cellular signaling pathways. Forskolin, through the elevation of cAMP, indirectly activates protein kinase A, which has the potential to phosphorylate and thereby enhance the activity of 1110018J18Rik, assuming its activity is modulated through phosphorylation events. Similarly, Sphingosine-1-phosphate may potentiate 1110018J18Rik's role in cytoskeletal dynamics by activating S1P receptors that influence the actin cytoskeleton, suggesting a possible interaction or dependency of 1110018J18Rik on these pathways. The direct activation of PKC by PMA could lead to phosphorylation events that enhance 1110018J18Rik's functional role, provided that 1110018J18Rik is a substrate for PKC or involved in related pathways. Additionally, the calcium ionophores Ionomycin and A23187, by increasing intracellular calcium levels, may promote the activation of calcium-dependent kinases that could phosphorylate 1110018J18Rik or influence its regulatory pathways. Epigallocatechin gallate and Genistein provide a mechanism for activation by inhibiting kinases that might normally suppress 1110018J18Rik's activity, suggesting a relief of inhibition as a means to enhance function.
Further contributing to the activation of 1110018J18Rik are inhibitors of key signaling enzymes, such as LY294002, PD98059, U0126, which by inhibiting PI3K, MEK, and MEK1/2, respectively, may upregulate alternative pathways or relieve negative feedback loops that could include 1110018J18Rik. Thapsigargin's inhibition of the SERCA pump leads to increased cytosolic calcium, potentially activating calcium-mediated signaling pathways and enhancing 1110018J18Rik's activity if it is calcium-regulated. SB203580, as an inhibitor of p38 MAPK, may shift signaling towards pathways that activate 1110018J18Rik, illustrating how the inhibition of one pathway can lead to the activation of another. Collectively, these compounds, through their targeted biochemical actions, serve to enhance the functional activity of 1110018J18Rik by manipulating the cellular signaling landscape to favor its activation, without directly increasing its expression or requiring direct ligand binding.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
Sphingosine-1-phosphate engages with S1P receptors, which trigger intracellular signaling cascades influencing actin cytoskeleton rearrangement. This can potentially enhance the activity of 1110018J18Rik if it is functionally involved in cytoskeletal dynamics or related signaling. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA is a potent activator of protein kinase C (PKC), which phosphorylates a wide range of cellular proteins. Activation of PKC can lead to enhanced functional activity of 1110018J18Rik if it is regulated by PKC-mediated phosphorylation or is involved in PKC-related pathways. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Ionomycin is a calcium ionophore that increases intracellular calcium concentrations. This rise in calcium can activate calcium-dependent protein kinases, potentially leading to the activation of 1110018J18Rik if it is a substrate for these kinases or involved in calcium signaling pathways. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
A potent antioxidant that inhibits certain protein kinases, which could lead to a reduction in phosphorylation-dependent inhibition of pathways that 1110018J18Rik is involved in, thus enhancing its activity by relieving negative regulatory effects. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is an inhibitor of PI3K, which may upregulate pathways that 1110018J18Rik is involved in by decreasing PI3K/AKT signaling, leading to enhanced functional activity of 1110018J18Rik if it operates downstream or parallel to this pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of MEK, which may lead to compensatory activation of alternative pathways that could include the activation of 1110018J18Rik if it is involved in signaling cascades that are affected by MEK activity. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187 is a calcium ionophore that increases intracellular calcium levels, activating calcium-dependent proteins and pathways that could lead to the activation of 1110018J18Rik, assuming it is involved in or regulated by calcium-dependent processes. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin is a SERCA pump inhibitor that leads to an increase in cytosolic calcium levels. Elevated calcium can activate signaling pathways that may enhance the activity of 1110018J18Rik if it is part of or regulated by calcium-mediated signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is an inhibitor of p38 MAPK and can shift the balance of cellular signaling towards pathways not reliant on p38 MAPK activity, potentially enhancing the activity of 1110018J18Rik if it is part of these alternative pathways. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
Genistein is a tyrosine kinase inhibitor that may lead to increased activity of pathways where tyrosine kinase signaling is inhibitory. If 1110018J18Rik functions are suppressed by tyrosine kinase activity, its activity could be enhanced as a result of genistein action. | ||||||